Feasibility evaluation of parallel administration of nanoliposomal irinotecan and levofolinate in unresectable pancreatic cancer treatment

Abstract Background Nanoliposomal irinotecan (nal-IRI) combined with levofolinate (l-LV) and fluorouracil (5-FU) is an effective second-line treatment for unresectable pancreatic cancer. The approved dosing schedule comprises sequential administration of premedication, nal-IRI (90 min), and l-LV (120 min), followed by 5-FU (46 h). This study evaluated the feasibility of parallel administration to shorten total infusion time by comparing parallel and sequential administration schedules. Methods This retrospective study included patients who received the nal-IRI regimen between June 2020 and December 2024. Patients were divided into two groups according to the administration schedule: sequential administration (June to October 2020, n = 13) and parallel administration (November 2020 to December 2024, n = 98). The primary endpoint was the incidence of grade ≥ 3 neutropenia within 90 d of treatment initiation. Results Grade ≥ 3 neutropenia occurred in 15.4% of patients in the sequential‑administration group and 39.8% in the parallel‑administration group (unadjusted odds ratio, 3.64; 95% confidence interval, 0.76–17.30; P = 0.13). The incidence in the first cycle was 7.7% and 8.2% between the groups ( P = 1.00). The incidences of other grade ≥ 3 and all-grade adverse events also did not differ significantly between the groups. The incidences of febrile neutropenia and fever did not differ significantly between the groups (febrile neutropenia: 7.7% vs. 7.1%, P = 1.00; fever: 46.2% vs. 25.5%, P = 0.18). The parallel-administration group had a disease control rate of 48.8%, which did not differ significantly from that of the sequential-administration group (33.3%; P = 0.37). Parallel administration reduced the daily bed occupancy time by approximately 150 min. Conclusions Parallel administration of nal-IRI and l-LV may be operationally feasible for improving resource efficiency in outpatient chemotherapy units; however, its comparative safety relative to sequential administration remains uncertain because of imprecision in the effect estimates.

Authors

Institutions

Publication Details

Journal
Journal of Pharmaceutical Health Care and Sciences
Published
2026-11-15
DOI
https://doi.org/10.1186/s40780-026-00649-0
Primary Topic
Pancreatic and Hepatic Oncology Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Feasibility evaluation of parallel administration of nanoliposomal irinotecan and levofolinate in unresectable pancreatic cancer treatment

Mitsuru Sugawara, Yoh Takekuma, Kazuki Uchiyama, Tatsuhiko Sakamoto et al.
Journal of Pharmaceutical Health Care and Sciences
Pancreatic and Hepatic Oncology Research
article

Feasibility evaluation of parallel administration of nanoliposomal irinotecan and levofolinate in unresectable pancreatic cancer treatment

Mitsuru Sugawara, Yoh Takekuma, Kazuki Uchiyama, Tatsuhiko Sakamoto, Takuya Watanabe, Yoshitaka Saito, Yoshito Komatsu
article en

Abstract

Abstract Background Nanoliposomal irinotecan (nal-IRI) combined with levofolinate (l-LV) and fluorouracil (5-FU) is an effective second-line treatment for unresectable pancreatic cancer. The approved dosing schedule comprises sequential administration of premedication, nal-IRI (90 min), and l-LV (120 min), followed by 5-FU (46 h). This study evaluated the feasibility of parallel administration to shorten total infusion time by comparing parallel and sequential administration schedules. Methods This retrospective study included patients who received the nal-IRI regimen between June 2020 and December 2024. Patients were divided into two groups according to the administration schedule: sequential administration (June to October 2020, n = 13) and parallel administration (November 2020 to December 2024, n = 98). The primary endpoint was the incidence of grade ≥ 3 neutropenia within 90 d of treatment initiation. Results Grade ≥ 3 neutropenia occurred in 15.4% of patients in the sequential‑administration group and 39.8% in the parallel‑administration group (unadjusted odds ratio, 3.64; 95% confidence interval, 0.76–17.30; P = 0.13). The incidence in the first cycle was 7.7% and 8.2% between the groups ( P = 1.00). The incidences of other grade ≥ 3 and all-grade adverse events also did not differ significantly between the groups. The incidences of febrile neutropenia and fever did not differ significantly between the groups (febrile neutropenia: 7.7% vs. 7.1%, P = 1.00; fever: 46.2% vs. 25.5%, P = 0.18). The parallel-administration group had a disease control rate of 48.8%, which did not differ significantly from that of the sequential-administration group (33.3%; P = 0.37). Parallel administration reduced the daily bed occupancy time by approximately 150 min. Conclusions Parallel administration of nal-IRI and l-LV may be operationally feasible for improving resource efficiency in outpatient chemotherapy units; however, its comparative safety relative to sequential administration remains uncertain because of imprecision in the effect estimates.

Journal of Pharmaceutical Health Care and Sciences
Hokkaido University of Science (JP), Hokkaido University (JP), Hokkaido University Hospital (JP)
Pancreatic and Hepatic Oncology Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon